Colchicine in acute gout
http://www.100md.com
《英国医生杂志》
EDITOR—Cox rightly points out that a total dose of colchicine has been introduced to advice in the BNF (British National Formulary) in recent years and is now at a 6 mg limit. The advice that has not changed is the traditional high dose regimen of 1 mg, followed every two hours by 0.5 mg, until relief of pain is obtained or vomiting or diarrhoea occurs.1
In Ahern et al's study all patients given high dose colchicine developed diarrhoea or nausea in 12-36 hours with a mean dose of 6.7 mg2; many patients taking high doses who have been referred to us have gastrointestinal adverse effects below a total dose of 6 mg. We find that the total dose is not really relevant for acute situations with the low dose regimen.
Sivagnanam wonders if our patients settled because of the residual effect of the previously administered high dose colchicine that we had stopped; we only reintroduced colchicine, however, if the gout was not settling or was worsening. We have treated other patients with acute gout by using low dose colchicine from the beginning, and symptoms in these patients settled promptly and without adverse event.
Whether non-steroidal anti-inflammatory drugs (NSAIDs) are less toxic than colchicine is debatable, particularly compared with low dose colchicine. Normally we use NSAIDs first unless there are contraindications or adverse events, as seen in our cases. Intrasynovial steroids are not always practicable.
We cannot recommend intravenous colchicine and agree with Pawlotsky that although highly effective it should no longer be used, because of local and general complications associated with a risk of death.3
Ian Morris, consultant rheumatologist
ian.morris@kgh.nhs.uk
George Varughese, senior house officer, Peter Mattingly, consultant rheumatologist
Department of Rheumatology, Kettering General Hospital, Kettering, Northamptonshire NN16 8UZ
Competing interests: None declared.
References
Joint Formulary Committee. British national formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2003;(46): 497.
Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987;17: 301-4.
Pawlotsky Y. Treatment of gout. Rheumatol Eur 1996;25: 142-4.
濞ｅ洠鍓濇导鍛閸涱剛杩旈柛娆忓€介埀顒€鍠涚槐婵囩▔瀹ュ棛鈧垶骞嬮幇顏呭床濞达絾娲戠粻锝咁嚈妤︽鍞撮柕鍡曠劍鐢綊鎳￠幇顓炵仐闁圭ǹ娲ょ槐鈺呭Υ閸屾稒鐎紒鏃傚Х婢ф寮堕崘銊ф剑濞存粌楠哥敮顐︽媼濡炲墽绋婇柡澶婂暕濮瑰鏁嶅畝鍐仧闁诡喓鍔忛缁樼▔閻戞﹩鍔冮柡鍌氭矗缁楀鈧绮忛～锕傚绩鐠鸿櫣绉垮〒姘☉閵囧洨鈧娉涢崢銈囨嫻瑜版帗顫夐悹鍥︾串缁辨繄鎷犻悜钘変粡濞寸姾鍩栭崹銊╂偨娴ｅ啰妯堥梺顐ｆ皑閻擄繝骞嬮幋婊勭拨闁挎稑鏈崹婊勭椤掍焦鏆柛鎺嶅嵆閳ь剚姘ㄩ悡锟犲触鎼搭垳绀夊ù鍏兼皑閻濇盯宕￠崘鑼闁诡喓鍔庡▓鎴炴媴濠婂啯鎯傚ù鐘插濠€鎵磾閹寸姷褰查柛鎺斿█濞呭酣濡撮敓锟�In Ahern et al's study all patients given high dose colchicine developed diarrhoea or nausea in 12-36 hours with a mean dose of 6.7 mg2; many patients taking high doses who have been referred to us have gastrointestinal adverse effects below a total dose of 6 mg. We find that the total dose is not really relevant for acute situations with the low dose regimen.
Sivagnanam wonders if our patients settled because of the residual effect of the previously administered high dose colchicine that we had stopped; we only reintroduced colchicine, however, if the gout was not settling or was worsening. We have treated other patients with acute gout by using low dose colchicine from the beginning, and symptoms in these patients settled promptly and without adverse event.
Whether non-steroidal anti-inflammatory drugs (NSAIDs) are less toxic than colchicine is debatable, particularly compared with low dose colchicine. Normally we use NSAIDs first unless there are contraindications or adverse events, as seen in our cases. Intrasynovial steroids are not always practicable.
We cannot recommend intravenous colchicine and agree with Pawlotsky that although highly effective it should no longer be used, because of local and general complications associated with a risk of death.3
Ian Morris, consultant rheumatologist
ian.morris@kgh.nhs.uk
George Varughese, senior house officer, Peter Mattingly, consultant rheumatologist
Department of Rheumatology, Kettering General Hospital, Kettering, Northamptonshire NN16 8UZ
Competing interests: None declared.
References
Joint Formulary Committee. British national formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2003;(46): 497.
Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987;17: 301-4.
Pawlotsky Y. Treatment of gout. Rheumatol Eur 1996;25: 142-4.
|
鐎甸偊鍠曟穱濠囧棘閸モ晝褰�
闁稿繗娅曢弫鐐烘儌閻愵剙顎�
閻犲洤瀚鎴﹀礄閻樻彃缍�
闁瑰吋绮庨崒銊╁即閺夋埈妯�
闁规亽鍔岄悺銊х磼濞嗘劖绠欓柛娆欐嫹
闁告梻濮撮崣鍡涘绩閹増顥�
|